IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that Vicente
Anido, Jr., Ph.D., Chairman and Chief Executive Officer, and Richard
Rubino, Chief Financial Officer, will attend the following conferences
Jefferies 2017 Healthcare Conference
Presentation Date: Tuesday, June 6, 2017
Presentation Time: 10:30am E.T.
Location: New York, NY
JMP Securities Life Science Conference 2017
Presentation Date: Tuesday, June 20, 2017
Presentation Time: 11:30am E.T.
Location: New York, NY
The presentations will be webcast live and may be accessed by visiting
Aerie's website at http://investors.aeriepharma.com/.
A replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure-lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA (new drug
application) for RhopressaTM (netarsudil ophthalmic solution)
0.02% was submitted to the U.S. Food and Drug Administration (FDA) in
February 2017, and, in May 2017, the FDA set the PDUFA (Prescription
Drug User Fee Act) goal date for the completion of the FDA's review of
the RhopressaTM NDA for February 28, 2018. Aerie's second
product candidate, RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of
RhopressaTM and widely prescribed PGA latanoprost, achieved
its primary efficacy endpoint in two Phase 3 registration trials, named
Mercury 1, which is still ongoing, and Mercury 2. A RoclatanTM
NDA submission is expected to take place in the first half of 2018.
Aerie is also focused on the development of additional product
candidates and technologies in ophthalmology.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005038/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media